Search Results - "ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ"

1

Academic Journal

18FDG PET-CT significance for post-treatment monitoring in cervical and uterine cancer patients with suspected recurrence in previously irradiated zones ; Роль 18F-ФДГ ПЭТ-КТ в посттерапевтическом мониторинге у больных раком шейки и тела матки c подозрением на прогрессирование в ранее облученных зонах

Authors: V. A. Solodkiy, N. V. Nudnov, Yu. M. Kreynina, L. N. Shevchenko, M. Kh. Kaskulova, V. A. Titova, E. V. Pronkina, V. O. Vorobjeva, В. А. Солодкий, Н. В. Нуднов, Ю. М. Крейнина, Л. Н. Шевченко, М. Х. Каскулова, В. А. Титова, Е. В. Пронькина, В. О. Воробьева

Source: Medical Visualization; Том 27, № 2 (2023); 99-109 ; Медицинская визуализация; Том 27, № 2 (2023); 99-109 ; 2408-9516 ; 1607-0763

Subject Terms: чувствительность и специфичность, uterine cancer, PET-CT, MRI, radiation therapy, brachytherapy, chemo-radiation treatment, loco-regional recurrence, sensitivity and specificity, рак тела матки, ПЭТ-КТ, МРТ, лучевая терапия, броахитерапия, химиолучевое лечение, локорегионарный рецидив

File Description: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/1177/799; Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава России, 2022. 239 с. ISBN 978-5-85502-275-9.; Крейнина Ю.М., Титова В.А., Бурнашкина С.П. Современные подходы к применению магнитно-резонансной томографии в планировании и мониторинге высокомощностной брахитерапии гинекологического рака. Онкология. Журнал им. П.А. Герцена. 2014; 2: 81–82.; Титова В.А., Паньшин Г.А., Шевченко Л.Н., Крейнина Ю.М., Каскулова М.Х. Послеоперационная конформная лучевая терапия рака шейки и тела матки: роль контактной лучевой терапии. Трудный пациент. 2019; 17 (8–9): 33–36. http://doi.org/10.24411/2074- 1995-2019-10060; Аксенова С.П., Нуднов Н.В., Крейнина Ю.М. Магнитнорезонансная визуализация влагалища и малого таза у женщин, перенесших противоопухолевое лечение по поводу рака женских половых органов. Медицинская визуализация. 2017; 21 (2): 131–139. https://doi.org/10.24835/1607-0763-2017-2-131-139; Ашрафян Л.А., Тё С.А., Огрызкова В.Л., Крейнина Ю.М., Алешикова О.И. Трехмерная эхография при раке шейки матки. Медицинская визуализация. 2003; 2: 68–73.; Алимардонов Д.Б. Возможности позитронно-эмиссионной томографии в уточняющей диагностике рака шейки матки Ib-IIIb стадий: Дис. . кандидат медицинских наук. М., 2011. 107 c.; Stojiljkovic M., Sobic Saranovic D., Odalovic S. et al. FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI. Radiol Oncol. 2022; 56 (4): 453–460. http://doi.org/10.2478/raon-2022-0042; Yoon J.W., Kim S., Kim S.W. et al. PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation. Clin. Nucl. Med. 2016; 41 (9): 677–682. http://doi.org/10.1097/RLU.0000000000001269; Аретинский А.В., Терновой С.К. ПЭТ/КТ с 18F-FDG в уточняющей диагностике рака тела матки. Российский электронный журнал лучевой диагностики. 2018; 8 (3): 20–29. http://doi.org/10.21569/2222-7415-2018-8-3-20-29; Rockall A.G., Cross S., Flanagan S. et al. The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging. 2012. 5; 12 (1): 49–65. http://doi.org/10.1102/1470-7330.2012.0007; Perrone A.M., Dondi G., Coe M. et al. Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. Cancers (Basel). 2020; 12 (3): 659. http://doi.org/10.3390/cancers12030659; Sanei Sistani S., Parooie F., Salarzaei M. Diagnostic Accuracy of 18F-FDG-PET/CT and MRI in Predicting the Tumor Response in Locally Advanced Cervical Carcinoma Treated by Chemoradiotherapy: A Meta-Analysis. Contrast Media Mol. Imaging. 2021. 2; 2021: 8874990. http://doi.org/10.1155/2021/8874990; Lima G.M., Matti A., Vara G. et al. Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensityand volume-based PET parameters. Eur. J. Nucl. Med. Mol. Imaging. 2018; 45 (12): 2139–2146. http://doi.org/10.1007/s00259-018-4077-1; Scher N., Castelli J., Depeursinge A. et al. (18F)-FDG PET/ CT parameters to predict survival and recurrence in patients with locally advanced cervical cancer treated with chemoradiotherapy. Cancer Radiother. 2018; 22 (3): 229–235. http://doi.org/10.1016/j.canrad.2017.10.003; Han L., Wang Q., Zhao L. et al. A Systematic Review and Meta-Analysis of the Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Locally Advanced Cervical Cancer Treated with Concomitant Chemoradiotherapy. Diagnostics (Basel). 2021; 14; 11 (7): 1258. http://doi.org/10.3390/diagnostics11071258; Son S.H., Jeong S.Y., Chong G.O. et al. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy. Clin. Nucl. Med. 2018; 43 (9): e296–e303. http://doi.org/10.1097/RLU.0000000000002188; Auguste P., Barton P., Meads C. et al. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis. BJOG. 2014; 121 (4): 464–476. http://doi.org/10.1111/1471-0528.12460; Albano D., Zizioli V., Odicino F. et al.Clinical and prognostic value of 18F-FDG PET/CT in recurrent endometrial carcinoma. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2019; 38 (2): 87–93. https://doi.org/10.1016/j.remnie.2018.10.004; Саевец В.В., Важенин А.В., Чернова Л.Ф., Шимоткина И.Г., Мухин А.А., Таратонов А.В. Возможности позитронно-эмиссионной компьютерной томографии в оценке результатов лечения местно-распространенного рака шейки матки. Акушерство и гинекология: новости мнения, обучение. 2019; 7 (1): 46–51. http://doi.org/10.24411/2303-9698-2019-11006; Chung H.H., Jo H., Kang W.J. et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol. Oncol. 2007; 104 (3): 529–534. http://doi.org/10.1016/j.ygyno.2006.09.009; Dag Z., Yilmaz B., Dogan A.K. et al. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Brachytherapy. 2019; 18 (2): 154–162. http://doi.org/10.1016/j.brachy.2018.11.005; https://medvis.vidar.ru/jour/article/view/1177

Availability: https://medvis.vidar.ru/jour/article/view/1177
https://doi.org/10.24835/1607-0763-1177

View record from BASE

2

Report

Перспективы и ограничения ультразвуковой диагностики врожденных пороков развития плода в первом триместре беременности. Обзор

Subject Terms: чувствительность и специфичность УЗИ, врожденные пороки развития, congenital developmental defects, congenital heart defects: prenatal screening, пренатальный скрининг, ультразвуковое исследование, врожденные пороки сердца, ultrasound examination, sensitivity and specificity of ultrasound

3

Academic Journal

DIAGNOSTIC AND CLASSIFICATION CRITERIA IN RHEUMATOLOGY: WHEN SHOULD THE CRITERIA BE USED AND HOW DO THEY DIFFER? ; Диагностические и классификационные критерии в ревматологии: когда их применять и чем они различаются?

Authors: Yu. V. Muravyev, Ю. В. Муравьев

Source: Rheumatology Science and Practice; Vol 55, No 1 (2017); 8-11 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 8-11 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171

Subject Terms: чувствительность и специфичность критериев, diagnostic criteria, classification criteria, sensitivity and specificity of criteria, диагностические критерии, классификационные критерии

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2331/1536; June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28(6):921-34. doi:10.1016/j.berh.2015.04.004; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi:10.1002/art.27584; Aggarwal R, Liao K, Nair R, et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009;61(11):1472-83. doi:10.1002/art.24827; Johnson SR, Goek ON, Singh-Grewal D, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119-33. doi:10.1002/art.23018; Yazici H. Diagnostic versus classification criteria – a continuum. Bull NYU Hosp Jt Dis. 2009;67(2):206-8.; Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582-91. doi:10.1002/art.27580; Van den Hoogen F, Khanna D, Fransen J, еt al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47. doi:10.1002/art.38098; Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64(4):943-54. doi:10.1002/art.34356; Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348-52. doi:10.1002/art.22003; Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-10. doi:10.1002/acr.20140; Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8. doi:10.1002/art.1780270401; Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218-27. doi:10.1002/art.1780341003; Fries JF, Hochberg MC, Medsger TA Jr, et al. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1994;37(4):454-62. doi:10.1002/art.1780370403; Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129(5):345-52. doi:10.7326/0003-4819-129-5-199809010-00001; Fries JF, Siegel RC. Testing the 'preliminary criteria for classification of SLE'. Ann Rheum Dis. 1973;32(2):171-7. doi:10.1136/ard.32.2.171; Michet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proceedings. 1985;60(2):105-13. doi:10.1016/S0025- 6196(12)60294-8; Peat G, Greig J, Wood L, et al. Diagnostic discordance: we cannot agree when to call knee pain 'osteoarthritis'. FamPract. 2005;22(1):96-102. doi:10.1093/fampra/cmh702; Ziswiler HR, Urech R, Balmer J, et al. Clinical diagnosis compared to classification criteria in in a cohort of 54 patients with systemic sclerosis and associated disorders. Swiss Med Wkly. 2007;137(41-42):586-90.; Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343-8.; Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exper Nephrol. 2013;17(5):619-21. doi:10.1007/s10157-013-0854-0; Dalbeth N, Fransen J, Jansen TL, et al. New classification criteria for gout: a framework for progress. Rheumatology. 2013;52(10):1748-53. doi:10.1093/rheumatology/ket154; Hunder GG. The use and misuse of classification and diagnostic criteria for complex diseases. Ann Intern Med. 1998;129(5):417-8. doi:10.7326/0003-4819-129-5-199809010-00013; Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891-7. doi:10.1002/acr.22583

Availability: https://rsp.mediar-press.net/rsp/article/view/2331
https://doi.org/10.14412/1995-4484-2017-8-11

View record from BASE

4

Academic Journal

ОПРЕДЕЛЕНИЕ ЗНАЧИМОЙ БАКТЕРИУРИИ У БЕРЕМЕННЫХ ЖЕНЩИН МЕТОДОМ КОЛИЧЕСТВЕННОЙ ПОЛИМЕРАЗНОЙ ЦЕПНОЙ РЕАКЦИИ В РЕАЛЬНОМ ВРЕМЕНИ

Authors: ХУСНУТДИНОВА ТАТЬЯНА АЛЕКСЕЕВНА, ШИПИЦЫНА ЕЛЕНА ВАСИЛЬЕВНА, САВОЧКИНА ЮЛИЯ АНАТОЛЬЕВНА, ТИМОШИНА ОЛЬГА ЮРЬЕВНА, РЫБИНА ЕЛЕНА ВЛАДИМИРОВНА, ГУЩИН АЛЕКСАНДР ЕВГЕНЬЕВИЧ, САВИЧЕВА АЛЕВТИНА МИХАЙЛОВНА

Subject Terms: ИНФЕКЦИИ МОЧЕВЫВОДЯЩИХ ПУТЕЙ,ЗНАЧИМАЯ БАКТЕРИУРИЯ,УРОПАТОГЕНЫ,КОЛИЧЕСТВЕННАЯ ПЦР В РЕАЛЬНОМ ВРЕМЕНИ,ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ,URINARY TRACT INFECTIONS,SIGNIFICANT BACTERIURIA,UROPATHOGENS,QUANTITATIVE REAL-TIME PCR,SENSITIVITY AND SPECIFICITY

File Description: text/html

Availability: http://cyberleninka.ru/article/n/opredelenie-znachimoy-bakteriurii-u-beremennyh-zhenschin-metodom-kolichestvennoy-polimeraznoy-tsepnoy-reaktsii-v-realnom-vremeni
http://cyberleninka.ru/article_covers/16947583.png

View record from BASE

5

Academic Journal

СРАВНИТЕЛЬНАЯ ОЦЕНКА СОВРЕМЕННЫХ МЕТОДОВ ПЕРИМЕТРИИ В ДИАГНОСТИКЕ НАЧАЛЬНОЙ СТАДИИ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМЫ

Authors: Сухорукова, Алена, Шутова, Светлана

Subject Terms: ГЛАУКОМА, ПЕРИМЕТРИЯ, ДИАГНОСТИЧЕСКАЯ ИНФОРМАТИВНОСТЬ, ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ МЕТОДА

File Description: text/html

Availability: http://cyberleninka.ru/article/n/sravnitelnaya-otsenka-sovremennyh-metodov-perimetrii-v-diagnostike-nachalnoy-stadii-otkrytougolnoy-glaukomy
http://cyberleninka.ru/article_covers/15760547.png

View record from BASE

6

Academic Journal

Diagnostic value of [-2]proPSA and PHI index (review of literature) ; Диагностическая значимость [-2]proPSA и PHI (обзор литературы)

Authors: A. V. Sidorenkov, A. V. Govorov, A. V. Sadchenko, D. Yu. Pushkar, А. В. Сидоренков, А. В. Говоров, А. В. Садченко, Д. Ю. Пушкарь

Source: Cancer Urology; Том 10, № 4 (2014); 87-95 ; Онкоурология; Том 10, № 4 (2014); 87-95 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-4

Subject Terms: чувствительность и специфичность метода, biomarker, prostate-specific antigen, [-2]proPSA, PHI index, prostate biopsy, sensitivity and specificity of the method, биомаркер, простат-специфический антиген, PHI, биопсия предстательной железы

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/403/420; Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581–92.; Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62(4):220–41.; Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37:4–66.; Cancer incidence in Sweden 2004. The National Board of Health and Welfare: Stockholm. http://sjp.sagepub.com/cgi/reprint/34/67_suppl/3.pdf.; Schroder F.H., Hugosson J., Roobol M.J. et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–28.; Andriole G.L., Crawford E.D., Grubb R.L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–19.; Noldus J., Graefen M., Haese A. et al. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38; 74–78.; Лоран О.Б., Пушкарь Д.Ю., Степанов В.П., Крохотина Л.В. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простатспецифического антигена сыворотки крови. М., 2000.; Лоран О.Б., Пушкарь Д.Ю., Франк Г.А. Простатспецифический антиген и морфологическая характеристика рака предстательной железы: Руководство для врачей. М.: МЕДпресс, 1999.; Bangma C.N., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma. J Urology 1997;157: 544–7.; Catalona W.J. Clinical utility of measurements of free and total prostatespecific antigen (PSA). Prostate 1996; : 64–9.; Seamen E., Whang M. Prostate-specific antigen3 density (PSAD): pole in patient evaluation and management. Urol Clin North Am 1993;20:653–6.; Cuvillier O., Malavaud B. Biomarkers of aggressiveness in prostate cancer. Prostate cancer – diagnostic and therapeutic advances. November 2011;3–20.; Пушкарь Д.Ю., Говоров А.В. Маркеры рака предстательной железы. Экспериментальная и клиническая урология 2001; 2–3:19–21.; Mikolajczyk S.D., Marker K.M., Millar L.S. et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958–63.; Peter J., Unverzagt C., Krogh T.N. et al. Identification of precursor forms of prostatespecific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61:957–62.; Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59:797–802.; Chen Z., Chen H., Stamey T.A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157:2166–70.; Zhang W.M., Leinonen J., Kalkkinen N. et al. Purification and characterization of different molecular forms of prostatespecific antigen in human seminal fluid. Clin Chem 1995;41:1567–73.; Mikolajczyk S.D., Grauer L.S., Millar L.S. et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710–4.; Mikolajczyk S.D., Millar L.S., Wang T.J. et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55:41–5.; Mikolajczyk S.D., Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003;52:86–91.; Makarov D., Isharwal S., Sokoll L. et al. Pro-prostate-specific antigen мeasurements in serum and biopsy tissue predict the need for prostate cancer treatment among men enrolled in an expectant management program. Clin Cancer Res 2009;15:7316–21.; Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSA in the detection and management of early prostate cancer. BJU International 2013;112:6.; Sokoll L.J., Chan D.W., Mikolajczyk S.D. et al. Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology 2003;61:274–6.; Khan M.A., Partin A.W., Rittenhouse H.G. et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170:723–6.; Sokoll L.J., Wang Y., Feng Z. et al. [-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008;180:539–43.; Catalona W.J., Bartsch G., Rittenhouse H.G. et al. Serum pro-prostate specific antigen cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171:2239–44.; Stephan C., Kahrs A.M., Cammann H. et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69(2):198–207.; Le B.V., Griffin C.R., Loeb S. et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183(4):1355–9.; Catalona W.J., Partin A.W., Sanda M.G. et al. A Multicenter study of [–2]Pro-Prostate- Specific Antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range. J Urol 2011;185:1650–5.; Jansen F.H., van Schaik R.H., Kurstjens J. et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57(6):921–7.; Guazzoni G., Nava L., Lazzeri M. et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60(2):214–22.; Lazzeri M., Haese A., Abrate A. et al. Clinical performance of serum prostatespecific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112(3):313–21.; Catalona W.J., Bartsch G., Rettenhous H.G. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170:2181–5.; Khan M.A., Sokoll L.J., Chan D.W. еt al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology. 2004;64(6):1160–4.; Sokoll L.J., Sanda M.G., Feng Z. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193–200.; Vincendeau S., Ramirez J. The beckman coulter prostate health index (phi) improves diagnostic accuracy in prostate cancer detection. Eur Urol Suppl 2010;9:309.; Guazonni G., Lazzeri M., Nava L. et al. Preoperative prostate-specific antigen isoform p2PSA and its derivates, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455–66.; Filella X., Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51(4):729–39.; Houlgatte A., Vincendeau S., Desfemmes F. et al. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients]. Prog Urol 2012;22(5):279–83.; Lughezzani G., Lazzeri M., Larcher A. et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012;188:1144–50.; Lazzeri M., Briganti A., Scattoni V. et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 2012; 88(4):1137–4.; Lazzeri M., Haese A., de la Taille A. et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013; 63(6): 986–94.; Roobol M.J., Semjonow A., Bangma C.H. Performance of the ERSPC risk calculator for high grade prostate cancer in a clinical setting and the additional value of the Prostate Health Index (PHI®). J Urol Suppl 2011:139.; Carter H.B., Walsh P.C., Landis P., Epstein J.I. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231–4.; Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185.; Epstein J.I., Walsh P.C., Carmichael M. Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74.; Mohler J., Bahnson R.R., Boston B. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162–200.; Tosoian J.J., Loeb S., Feng Z. et al. Association of [–2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. J Urol 2012;188: 1131–6.; https://oncourology.abvpress.ru/oncur/article/view/403

Availability: https://oncourology.abvpress.ru/oncur/article/view/403
https://doi.org/10.17650/1726-9776-2014-10-4-87-95

View record from BASE

7

Academic Journal